R&D
Bio Bank Healing develops new drugs for intestinal microbiota
Pipeline
| Treatment area | Pipeline NO. | Indication | Discovery | Non-clinical | Clinical | |
|---|---|---|---|---|---|---|
| Candidate material discovery | Effectiveness evaluation | GLP toxicity test | Phase 1 clinical trial | |||
| lntestinal disease |
BBH-021 BBH-020 BBH-024 BBH-019
|
Clostridium Difficile Infection Inflammatory Bowel Disease Irritable Bowel Syndrome
|
|
|||
| Allergic disease |
BBH-016 BBH-020 BBH-021 BBH-019 BBH-024
|
Asthma Allergic disease
|
|
|||
| CNS Disease |
BBH-018 BBH-019 BBH-020 BBH-021 BBH-023 BBH-024
|
Parkinson's disease Alzheimer's disease
|
|
|||
| Cancer |
BBH-010 BBH-017 BBH-019
|
Stomach cancer Colorectal cancer Immuno Oncology
|
|
|||
| liver disease |
BBH-010
|
Non-alcoholic steatohepatitis
|
|
|||
FOOTER 
Privacy Policy
- Bio Bank Healing
- CEO. Dongho Lee
- 2F, Healthcare Innovation Part, Seoul National University Hospital Bundang, 172 Dolmar-ro, Bundang-gu, Seongnam-si, Gyeonggi-do
- TEL. 070-4282-0042~3
- FAX. 031-738-0142
- E-MAIL. bbhsnubh1010@gmail.com
© biobankhealing Corp. All rights reserved.